C urrent initiatives to treat human cancer by genetic intervention are a consequence of the relative lack of success of conventional approaches to therapy of cancer together with rapid progress in our understanding of cancer biology at both molecular and cellular levels. Similar to conventional chemotherapy and radiotherapy, a formidable task faced by gene therapy is the specificity of therapeutic gene expression for cancer cells. 1, 2 Unlike their normal counterparts, tumor cells often possess an unlimited proliferation potential and display a high degree of heterogeneity, which is ultimately caused by alterations in patterns of gene expression. The promoters for the genes whose expression is limited to, or elevated in, a given subset of tumor cells have been tested for their suitability to direct therapeutic gene expression to the corresponding classes of tumor cells. 3 For example, with the promoters of the carcinoembryonic antigen and ␣-fetoprotein genes for hepatocarcinoma 4, 5 and of the tyrosinase gene for melanoma, 6 tumor-specific targeting of gene expression has been achieved both in cell culture and in animal models. However, whether any of these examples can repeat their success in a clinical setting remains to be seen.
The TP53 gene is mutated in Ͼ50% of major human tumors derived from Ͼ50 different cell and tissue types. 7, 8 This underlines the paramount importance of the TP53 gene in the prevention of cell transformation. In addition to mutation, inactivation of p53 may occur without a change in its sequence. Both viral and cellular oncoproteins can inhibit p53 function through proteinprotein interaction, either by inducing rapid degradation or by sequestering it in an inactive form. 9, 10 Inactivation of p53 may also occur when it fails to enter the nucleus, where it is required for its normal function. 11, 12 The tumor suppressor activity of p53 is related to its ability to interact with both DNA and proteins. As a result of complex patterns of both DNA-protein and protein-protein interactions, expression of the downstream genes that participate in the control of DNA replication, repair, cell cycle, and apoptosis can be either elevated or decreased by p53. 13 We have exploited the loss of both a positive and negative role of p53 in the control of gene transcription in tumors to develop a gene targeting approach designated to allow maximal expression of a potential therapeutic gene in p53 null or mutant tumor cells, while actively switching the same gene off in normal cells. In this report, we have used reporter gene assays to demonstrate the feasibility of this approach and its potential for future clinical applications of gene therapy.
MATERIALS AND METHODS

Gene constructs
Unit I constructs. A 133-base pair (bp) fragment of heat shock protein 70 (Hsp70) promoter region (Ϫ117 to ϩ26) 14 was amplified with PFU DNA polymerase (primers: sense, Hsp70a 5Ј-atGGATCCgcgaaacccctggaatattcccgacct-3Ј; antisense, Hsp70b 5Ј-cgGGATCCgcagctcctcaggctattcgttatcc-3Ј) and cloned into pcrSKCAM (Stratagene, La Jolla, Calif) to create Hsp70sk. The 1.96-kilobase HindIII/SalI fragment containing firefly luciferase (Luc) and a poly(A) addition signal from pGL3basic (Promega, Madison, Wis) were cloned at the same sites of Hsp70sk to create Hsp70Luc. The 470-bp HindIII fragment of pOP13CAT (Stratagene), in which three copies of the lactose operator (LacO) sequence are located within an intron sequence, was cloned at the same site of Hsp70Luc in the correct orientation to produce Hsp70lacoLuc. A 316-bp SmaI/XhoI fragment containing seven copies of the tetracycline (tet) operator (tetO) sequence from ptetO7-tk-L 15 was cloned at the NotI site of Hsp70Luc in the correct orientation to make tetO7Hsp70Luc. The 145-bp BamHI fragment containing the Hsp70 promoter of Hsp70sk was inserted at the SmaI site of pRL-null (Promega) to create Hsp70rLuc.
Unit II constructs. A GC3p53 oligonucleotide (sense, 5Ј-GCCC(GGACTTGCCT) 2 -3Ј; antisense, 5Ј-(AGGCA AGTCC) 2 GGGC-3Ј) from the human retinoblastoma promoter 16 was cloned in both orientations at the SmaI site of pt109, where the firefly Luc gene is under the control of the herpes simplex virus thymidine kinase (HSV-tk) promoter (Ϫ109 to ϩ52), 17 to create GC3p53tkLuc-14 and GC3p53tkLucϩ16. The HindIII/ BglII fragment containing the GC3p53tk promoter element in GC3p53tkLuc-14 was transferred to the SmaI/ BglII sites of pGL3basic (Promega). Subsequently, both GC3p53tklacR and GC3p53tktetR were made by replacing the firefly Luc gene with (a) the Lac repressor (LacR) gene from pSЈ33, where the LacR gene is under the control of the F9-1 polyoma promoter (Stratagene), or (b) the tet repressor (tetR)/KRAB (tet repressor linked to the DNA suppression domain of Drosophila KRAB protein) gene from CMVtetR/KRAB. 15 For the antisense Luc constructs, the 200-bp BglII/SalI fragment of GC3p53tkLuc-14 (containing the GC3p53tk promoter) was inserted at the XbaI/SalI sites of pGL3basic to create GC3p53tkaLuc-poly(A). Next, the 200-bp XbaI/BamHI fragment containing the poly(A) additional signal was inserted at HindIII/BglII sites of GC3p53tkaLuc-poly(A) to make GC3p53tkaLuc. GC3p53tkaLuc was cut by PstI/Bcl-2 to delete the 3Ј part of the Luc gene region (from ϩ512 to ϩ1743 bp) and religated to create GC3p53tkaLuc Ϫ . To make CMVaLuc, the 1.7-kilobase PstI/XhoI fragment from GC3p53tkaLuc-poly(A) was cloned at the same sites of the pCI vector (Promega).
p53 constructs. The CMVwtp53 construct, in which the wild-type p53 (wtp53) gene is under the control of the cytomegalovirus (CMV) promoter, was obtained from R. Brown (Glasgow, UK). The mutant p53 (mtp53) constructs 245gly3ser (245g3s), 248arg3gln (248r3w), 249arg3ser (249r3s), and 273arg3his (273r3h) were created by polymerase chain reaction mutagenesis with CMVwtp53 as the template by using the QuickChange Site-Directed Mutagenesis Kit (Stratagene) with the following primers: 245 sense, 5Ј-ctg cat ggg cga cat gaa ccg g-3Ј; 245 antisense, 5Ј-ccg gtt cat gtc gcc cat gca g-3Ј; 248 sense, 5Ј-cgg cat gaa cca gag gcc cat c-3Ј; 248 antisense, 5Ј-gat ggg cct ctg gtt cat gcc g-3Ј; 249 sense, 5Ј-cat gaa ccg gag tcc cat cct cac-3Ј; 249 antisense, 5Ј-gtg agg atg gga ctc cgg ttc atg-3Ј; 273 sense, 5Ј-ctt tga ggt gca tgt ttg tgc ctg-3Ј; and 273 antisense, 5Ј-cag gca caa aca tcg acc tca aag-3Ј.
The mtp53 constructs 143ala3val (143a3v) and 216ala3gly (216a3g) were obtained from K. Parkinson; 175arg3his (175r3h) was obtained from D. Lane (Dundee, UK).
Cell cultures and transfection assays
K562 cells (p53
, the human myeloid leukemia cell line JCL 243, American Type Culture Collection, Manassas, Va) were maintained in Eagle's minimal essential medium with 2ϫ amino acids and vitamins supplemented with 5% fetal calf sera (Life Technologies, Gaithersburg, Md). Transfection of DNA construct (1 g each construct in 40 L of TE buffer) (10 mM tris(hydroxymethyl)aminomethane-HCl (pH 8.0), 1 mM ethylene diaminetetraacetic acid) to 0.4 mL K562 cells (2-10 ϫ 10 6 cells/mL) by electroporation with Flowergen Easyject (Straffordshire, UK) was carried out at 260 V and 1050 C. All experiments were performed in triplicate. After overnight culture, the cell extracts were made collectively from three identical transfections and assayed for Luc activity (if necessary, the Renilla Luc (rLuc) activity was measured subsequently), according to the manufacturer's recommendation (Promega), with a single photo channel in a Packard scintillation counter (Meriden, Conn). Each set of experiments was repeated once. The relative reporter gene expression was calculated as a ratio of that with the CMV vector control, arbitrarily taken as 1. The mean and SD were calculated from two sets of experiments.
For immunoblotting analysis of p53 protein, equal amounts (50 g) of protein extracts from each transfection experiment were electophoretically analyzed on 7.5% sodium dodecyl sulfate-polyacrylamide gels and electroblotted onto nitrocellulose paper. p53 protein was probed with DO-1 anti-human p53 antibody (a gift of D. Lane) and detected with enhanced chemiluminescence technology (Amersham, Arlington Heights, Ill).
RESULTS
A dual control system for targeting gene expression to tumor cells lacking wtp53 function
The "dual control system" consists of two genetic units. For unit I, the gene of therapeutic value (for proof of principle, Luc reporter genes are used instead of a therapeutic gene) is driven by a promoter that is sensitive to repression by p53. It is expected that expression of the gene in unit I will be significantly lower in normal cells than in tumor cells, where wtp53 repression is absent. We have chosen the human Hsp70 promoter as the promoter in unit I (Fig 1A) for the following reasons: (a) Elevated expression of the human Hsp70 protein observed in tumor cells seems to be closely linked with a more advanced stage and with poor prognosis 18 and may aid the survival of tumor cells after treatment with hyperthermia or chemotherapeutic drugs; 19 14 To further enhance the discrimination between tumor and normal cells contributed by the unit I construct, an additional genetic unit (unit II) was included, where the expression of genes whose products are able to suppress the expression of the unit I gene is controlled by a promoter containing p53 binding sites. 20 -23 It has been shown that a GCCC element is able to enhance p53-dependent transactivation on a neighboring p53 binding site in the human retinoblastoma gene promoter as much a 5-fold. 16 Therefore, we put both GCCC and two copies of the p53 binding site (GC3p53 element) upstream of the HSV-tk promoter to form the backbone of the unit II construct. In addition to a test construct expressing firefly Luc reporter, we have made unit II constructs that are designated to repress the expression of Luc from unit I. We considered various methods of suppression, including the genes encoding antisense Luc RNA, the LacR, or the suppression domain of Drosophila KRAB protein linked to the tetR (tetR/KRAB) (Fig 1B) . In the latter two cases, appropriate recognition elements for LacR (LacO) or for tet/KRAB (tetO) were inserted near the Hsp70 promoter in unit I (Fig 1A) . Stimulation of expression of the genes in these unit II constructs by p53 would further suppress the expression of the reporter gene driven by the Hsp70 promoter in unit I. Thus, inclusion of the unit II construct should have the effect of increasing the window of expression between tumor and normal cells of any gene inserted in unit I, in comparison with the unit I construct on its own (Fig 1C) .
Expression of the genes in both units of the dual control system correlates with cellular p53 status To determine the effect of cellular p53 status on gene expression in the dual control system without the potential complications associated with the unavoidable variation among cell lines, we chose a p53 Ϫ/Ϫ cell line, K562 human myeloid leukemia cells, 24 as the recipient for transient-transfection assays with Luc genes as reporters. It has been shown that the element(s) responsible for p53-mediated repression of the Hsp70 promoter is located between nucleotides Ϫ144 and Ϫ73.
14 Therefore, we cloned the human Hsp70 promoter (Ϫ154 and
K562 cells were transfected with both Hsp70rLuc and GC3p53tkLuc-14 reporter constructs along with various amounts of the CMVwtp53 construct. Both Luc and rLuc activities were measured. In parallel with increased CMVwtp53 inputs (0.5, 1, and 1.5 g), the relative rLuc activity, reflecting wtp53 suppression of the Hsp70 promoter activity in unit I, decreased from 1 with CMV vector control to 0.78, 0.6, and 0.48, respectively (Fig 2A,  columns 1-4) . Alternatively, the relative Luc activity, indicating transactivation of the GC3p53tk promoter in unit II by wtp53, increased from 1-to 27-, 89-, and 110-fold, respectively (Fig 2B, columns 1-4) .
To demonstrate that the mtp53 status of a cell has no effect on the transcription of both unit I and II promoters, we performed a comparable experiment with each of seven mtp53 constructs. Among mtp53 constructs, we included four hot-spot mutants: 175r3h, 248arg3trp (248r3w), 249r3s, and 273r3h, which collectively account for nearly 30% of the mutations in human tumors. 21 As expected, neither suppression of the Hsp70 promoter activity nor transactivation of the GC3p53tk promoter were observed (Fig 2, A and B, columns 5-11) . Analysis of protein extracts by Western blotting showed expression of the p53 constructs in transfected cells (Fig 2C) .
Suppression of expression of the unit I gene by a unit II construct expressing antisense Luc RNA Because both units in the dual control system respond to cellular p53 status in a predictable fashion (Fig 2) , a further wtp53-dependent repression of gene expression in unit I should be achieved with a unit II construct that encodes a molecule capable of suppressing expression of the unit I gene. We first tested the antisense RNA strategy, because some antisense RNAs are able to effectively suppress gene expression in a sequence-specific manner. 25 Two antisense constructs specific to the firefly Luc mRNA were made, where the antisense version of the full-length Luc mRNA (GC3p53tkaLuc) or its 5Ј part (from ϩ1 to ϩ582) (GC3p53tkaLuc Ϫ ) were put under the control of the GC3p53tk promoter (derived from GC3p53tkLuc-14). When cells were transfected with both the Hsp70Luc reporter construct (Hsp70Luc) and CMVaLuc, in which the antisense version of the full-length Luc gene was driven by the CMV promoter, the relative Luc activity was reduced to 0.37 ( Fig 3A, column 4) , indicating the feasibility of this strategy. Whereas wtp53 repression of the Hsp70 promoter led a reduction of the relative Luc activity to 0.57, inclusion of the unit II constructs GC3p53tkaLuc or GC3p53tkaLuc
Ϫ resulted in a reduction of this activity to 0.48 and 0.25, respectively. This observation reflects the repression of Luc expression by a higher level of expression of Luc antisense RNAs, as a result of p53-mediated transactivation of the unit II promoter. It was also noticed that the GC3p53tkaLuc Ϫ construct, which contains only the 5Ј part of the Luc gene (from ϩ1 to ϩ582), gave a stronger suppression than GC3p53tkaLuc (Fig 3A, columns 6 and 9 ). As predicted, there was no reduction of the relative level of Luc expression by a mtp53 construct, 143a3v, irrespective of the presence of antisense constructs (Fig 3A, columns 3, 7, and 10) .
Regulation of unit I expression by unit II incorporating either LacO/R or tetO/R transcription repression systems
The gene-specific nature of the antisense RNA approach makes it necessary to find the best design for each therapeutic gene, which can be a tedious process. By contrast, the control element-specific nature of the transcription repressor system makes the substitution of the Luc gene with any other gene, including those of therapeutic value, a relatively straightforward procedure.
The LacO/R system has been widely used for transcription suppression in eukaryotic systems, as demonstrated by its ability to inhibit transcription initiation as well as elongation. 26 We inserted three copies of the operator sequence between the Hsp70 promoter and the Luc gene to create a unit I construct, Hsp70lacoLuc. Cotransfection with a LacR construct in which the LacR gene is driven by a moderately potent promoter, F9-1 polyoma viral promoter (p3ЈSS), resulted in a reduction of the relative Luc activity from the vector control, 1, to 0.62. Whereas transfection of wtp53 produced a reduction of the relative Luc activity to 0.43 ( Fig 4A, columns  1-3) , a further reduction to 0.35 was obtained when a unit II construct, GC3p53tklacR, where the LacR gene was under the control of GC3p53tk element, was also included for transfection. In contrast, inclusion of a mtp53 construct (143a3v) alone or with GC3p53tklacR did not alter the relative level of Luc activity (Fig 4A,  columns 1, 5, and 6 ).
We have further tested the suitability of the tetO/R system, where the repressor gene consists of the suppression domain of the Drosophila KRAB gene and the DNA binding domain of the tetR. 15 Seven copies of the tetO sequence were inserted upstream of the Hsp70 promoter in Hsp70Luc to create tetO7Hsp70Luc as the unit I construct (Fig 5B) . For the unit II construct, the hybrid gene (tetR/KRAB) was put under the control of the GC3p53tk promoter to create GC3p53tktetR. Cotransfection of CMVtetR/KRAB, where the tetR/KRAB Figure 2 . Effect of p53 on gene expression in units I and II. K562 cells were transfected with 1 g each of Hsp70rLuc (unit I) and GC3p53tkLuc-14 (unit II) along with CMVwtp53 (columns 2-4) and seven CMVmtp53 constructs (columns 5-11) in triplicate. Cell extracts from each triplicate were assayed for both firefly Luc and rLuc activity, respectively. The Luc activity of the transfection-containing CMV vector was arbitrarily taken as 1 (column 1). The activities relative to that of the CMV vector were calculated. Both the mean and SD of the relative activities from two sets of experiments are illustrated for rLuc (unit I) (A) and for Luc (unit II) (B). C: The presence and relative levels of p53 in each transfection by immunoblotting analysis with an anti-p53 antibody (DO-1).
gene was driven by the powerful CMV promoter, brought the relative Luc activity down to 0.24 ( Fig 5A,  columns 1 and 2 ). Whereas transfection with CMVwtp53 reduced the relative Luc expression to 0.46 ( Fig 5A,  column 3 ), further inclusion of GC3p53tklacR in the transfection resulted in an additional reduction of the relative Luc activity to 0.33 ( Fig 5A, column 4) . Again, Luc expression was not affected by cotransfection with the 143a3v construct in a comparable experiment ( Fig  5A, columns 5 and 6 ).
DISCUSSION
p53 binds to two copies of the 10-mer sequence (5Ј-RRRCA/TT/AGYYY-3Ј) and transactivates genes whose promoter has such a sequence within or nearby. 13, [27] [28] [29] The relevance of this transactivating ability to the tumor suppressor function of p53 is reflected by the fact that ϳ80% of natural genetic changes in TP53 are missense mutations, which are largely confined to its evolutionarily well-conserved and sequence-specific DNA binding central region. 30, 31 Furthermore, ϳ30% of mutations are concentrated at several hot spots (e.g., 175r3h, 248r3w, 249r3s, and 273r3h), the original residues of which either directly contact the DNA or preserve the structural integrity of the domain required for DNA binding. 31 The overwhelming majority of mtp53 molecules have lost the DNA sequence-specific binding capacity necessary for p53 transactivation of gene expression, 27, 28, 32 demonstrating the importance of this property for tumor suppressor function. 33 p53 also suppresses the transcription of a number of cellular and viral genes with promoters that are devoid of the consensus sequence recognized by p53, including c-fos, c-jun, interleukin-6, 34 Hsp70, 14 proliferating cell nuclear antigen, 35 multidrug resistance gene (MDR1) 36 topoisomerase IIa, 37 and Bcl-2. 38 The interaction of p53 with both general transcription factors such as TATA-binding protein 39, 40 and/or transcriptional activators such as CCAAT box binding protein 41 is involved in these processes. Compelling evidence has indicated that such repressing activity is an important component of the tumor suppressor function of p53. 13 Furthermore, some mtp53 proteins are unable to repress but able to stimulate the transcription of several cellular and viral pro- moters, including that of human Hsp70, 14 proliferating cell nuclear antigen, 35 c-fos, 42 and MDR1. 36 This gain of function seems to parallel the oncogenic ability of those mtp53s demonstrated in both in vivo tumorigenicity assays 43, 44 and in vitro cell transformation assays of rat embryonic fibroblast cells. 45 The central role of p53 in preventing malignant transformation makes this gene an obvious target for use in cancer gene therapy. The observation that overexpression of wtp53 could lead tumor cells that have lost wtp53 function either to enter apoptosis or undergo cell cycle arrest 46, 47 has stimulated various attempts to restore p53 function by re-expressing the wtp53 gene in tumor cells 47, 48 or by introducing peptides which mimic the interaction between p53 and a C-terminal antibody, 49 resulting in a restoration of wtp53 conformation and function.
An alternative approach to p53-based tumor therapy involves the use of an adenoviral strain with no E1b function, the replication of which is suppressed by wtp53 but not by mtp53. This strategy has been used to target adenoviral replication specifically to the tumor cells, leading to lysis of the host cells with null or mtp53 status. 50 We have developed a different tumor targeting strategy that exploits the loss of wtp53 function with regard to its dual roles in the transcriptional regulation of gene expression. The results described in this report demonstrate that it is possible to use combinations of the unit I and II constructs to stimulate gene expression specifically in cells with null, mutant, or nonfunctional p53, while simultaneously repressing expression of the same gene in cells with wtp53. This approach differs from others that have been reported in that it does not depend upon the use of promoters reported to be tissue-specific or limited to certain tumor types. 3 The dual control system we have described should be applicable in therapy for Ͼ50% of human tumors showing a loss of p53 function. In addition, this system should be able to incorporate a number of different therapeutic genes, including both prodrug activating genes and immunomodulators. 51 Its future success is not dependent upon the specific targeting or selective delivery of the constructs to tumor cells (although it may be enhanced by the use of such approaches), because incorporation of the wtp53-dependent repressive elements in unit II should minimize expression in normal tissues and consequently reduce toxicity. Silencing of the therapeutic gene in normal cells may be further enhanced by the gene therapy procedure, because it is known that transfection itself induces wtp53 function. It may also be possible to improve the protective effect of wtp53 in normal tissues by prior treatment with minimal doses of a DNA-damaging agent, such as radiation, at levels that are sufficient to induce wtp53 stabilization and function but too low to cause any toxicity in patients. The testing of these concepts in vivo must await the availability of suitable animals models for cancer gene therapy. 
